MetXia gene therapy - Oxford BioMedica

Drug Profile

MetXia gene therapy - Oxford BioMedica

Alternative Names: MetXia; MetXia-MG; MetXia-P450; MetXia-VM; P450-GDEPT

Latest Information Update: 18 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Pancreatic cancer
  • Discontinued Breast cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2007 MetXia gene therapy is still in phase II trials for pancreatic cancer in the UK
  • 24 Mar 2005 A clinical study has been added to the adverse events and pharmacodynamics section
  • 16 Feb 2004 Phase-II clinical trials in Pancreatic cancer in United Kingdom (intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top